Research

Malaria Transmission Biology

Our research has led to the discovery of a mosquito-based malaria transmission-blocking vaccine (TBV) candidate (the AnAPN1 TBV), which has recently completed process development studies and is under consideration for First-In-Human trials in the near future.  
[Pictured:  Plasmodium falciparum male gamete “exflagellating”]

AnAPN1 Vaccine

It has been estimated that more than 1-2 million individuals succumb to Malaria every year, a majority of whom are children under the age of five. Plasmodium parasites, the causative agent of malaria, are transmitted to a vertebrate host by the infective bite of an Anopheles mosquito.
[Pictured: AnAPN1 antigen’s N-terminal region depicting key antibody epitopes in purple, green, blue and red]

Saliva-based Rapid Diagnostic Tests

Despite widespread malaria control efforts, residual malaria transmission continues to be observed, calling in to question whether the global malaria elimination goals can actually be achieved. A large proportion of this residual malaria parasite transmission is due to low numbers of parasites that cannot be detected by available blood-based rapid diagnostic tests (RDTs) or microscopy.
[Pictured: schematic of the saliva collection process]

Arbovirus Transmission Biology

We conduct both basic and applied research studies in the context of understanding mosquito-transmitted arbovirus transmission biology. This research includes viral pathogen surveillance in mosquitoes and ticks, Florida-relevant vector competence studies, insect-specific virus acquisition modes, as well as mosquito immunology and viral infection dynamics.
[Pictured: Aedes aegypti biting a finger. Image by Sean McCann]

Contact Us

Learn more about the research in the Dinglasan Laboratory.

Latest News

STAY UP TO DATE WITH OUR LATEST NEWS. LEARN ABOUT NEW DEVELOPMENTS, TREATMENTS, VACCINES, OUR LAB & MUCH MORE!

UF Malaria Researcher and Global Partners Win NIH Award for New International Center of Excellence

UF Malaria Researcher and Global Partners Win NIH Award for New International Center of Excellence

The cooperative agreement, from the National Institute of Allergy and Infectious Diseases, will establish a new International Center of Excellence in Malaria Research (ICEMR) focused

Read More
First in human clinical trials of the AnAPN1 malaria transmission-blocking vaccine

First in human clinical trials of the AnAPN1 malaria transmission-blocking vaccine

Former director of the PATH Malaria Vaccine Initiative, Christian Loucq, M.D., says it is exciting to see Dinglasan’s concept moving toward a clinical trial. “There

Read More